<DOC>
	<DOCNO>NCT01907087</DOCNO>
	<brief_summary>The purpose study determine whether BMN 190 safe effective treatment patient Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 ( CLN2 ) disease .</brief_summary>
	<brief_title>A Phase 1/2 Open-Label Dose-Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics , Efficacy Intracerebroventricular BMN 190 Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis ( CLN2 ) Disease</brief_title>
	<detailed_description>The purpose study determine whether BMN 190 safe effective treatment patient Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 ( CLN2 ) disease . This open label Phase 1/2 study conduct patient CLN2 disease . Efficacy measure ( disease rating scale MRI ) compare natural history control . The study conduct cGCP patient closely monitor .</detailed_description>
	<mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
	<criteria>Has diagnosis CLN2 determine TPP1 enzyme activity ( dry blood spot ) available study entry . If genotype information available , blood collect CLN2 gene analysis baseline . In addition , blood TPP1 enzyme activity ( dry blood spot ) collect baseline analyze centrally Has mild moderate disease document twodomain score 3 6 motor language domains Hamburg Scale , score least 1 two domain Written inform consent parent legal guardian assent subject , appropriate Has ability comply protocol requirement , opinion investigator Seizures stable judgement investigator Is less 3 year old enrollment Is 16 year old old enrollement Has another inherit neurologic disease , e.g . form CLN seizure unrelated CLN2 ( patient febrile seizure may eligible ) Has another neurological illness may cause cognitive decline ( e.g. , trauma , meningitis , hemorrhage ) study entry Requires ventilation support , except noninvasive support night Has receive stem cell , gene therapy , ERT CLN2 Has contraindication neurosurgery ( e.g. , congenital heart disease , severe respiratory impairment , clot abnormality ) Has contraindication MRI scan ( e.g. , cardiac pacemaker , metal fragment chip eye , aneurysm clip brain ) Has generalize motor status epilepticus within 4 week First Dose visit , take care status epilepticus clinical examination electroencephalogram ( EEG ) ( enrollment may postpone ) Has severe infection ( e.g. , pneumonia , pyelonephritis , meningitis ) within 4 week First Dose visit ( enrollment may postpone ) Is prone complication intraventricular drug administration , include patient hydrocephalus ventricular shunt Has know hypersensitivity component BMN 190 Has receive investigational medication within 30 day first infusion study drug schedule receive investigational drug BMN 190 course study Has medical condition extenuate circumstance , opinion investigator , might compromise subject 's ability comply protocol requirement compromise subject 's well , safety , clinical interpretability Has medical condition extenuate circumstance , opinion investigator , might compromise subject 's ability comply protocol require testing procedure compromise subject 's well , safety , clinical interpretability Pregnancy time study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Late infantile Neuronal Ceroid Lipofuscinosis Type 2</keyword>
	<keyword>LINCL</keyword>
	<keyword>NCL2</keyword>
	<keyword>CLN2</keyword>
	<keyword>Jansky-Bielschowsky disease</keyword>
</DOC>